Opinion statement
Few prospective, randomized, placebo-controlled trials have been performed to guide clinicians in the management of neuropathies seen in the setting of monoclonal gammopathies (paraproteins). Recommendations must be made on the basis of clinical experience and information gleaned from various uncontrolled and open-label trials. In every instance, decisions concerning therapy must be based on the clinical setting in which the paraprotein occurs.
-
•Treatment of paraproteinemic neuropathies associated with multiple myeloma, amyloidosis, and Waldenström’s macroglobulinemia should be directed at the treatment of the underlying disease. These neuropathies often remain recalcitrant to therapy.
-
•If the paraprotein results from cryoglobulinemia due to hepatitis C virus infection, interferon-α (with or without ribavirin) provides optimal subjective and objective relief from symptoms.
-
•For neuropathy associated with osteosclerotic myeloma (POEMS syndrome) and solitary bone lesions, radiation therapy is the most effective and least toxic initial therapy.
-
•In those patients with monoclonal gammopathies of undetermined significance (MGUS), consideration of the clinical syndrome may be very helpful in selecting appropriate treatment. Patients who fulfill diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are best treated in a manner similar to that used for idiopathic CIDP (ie, with intravenous immunoglobulin, plasma exchange, and corticosteroids).
-
•Class I evidence documents plasma exchange to be effective in peripheral neuropathies associated with MGUS of the IgG and IgA, but not IgM, types.
-
•The most difficult cases to treat are those with peripheral neuropathies associated with IgM monoclonal gammopathies, with or without reactivity to myelin-associated glycoprotein (MAG). A number of published case series propose therapeutic regimens for these conditions, yet optimal treatment remains to be established. In many cases, mildly symptomatic patients should not be subjected to the morbidity associated with current treatment regimens. In those patients requiring treatment, this author initially tries plasma exchange, followed by a course of chlorambucil if the symptoms and signs are predominantly sensory. For cases with rapid progression or significant disability, a regimen of monthly pulses with prednisone and cyclophosphamide is recommended. If improvement does not ensue, a trial of a newer agent, such as rituximab, is recommended.
-
•Supportive treatment with physical therapy, orthotics, and ambulatory aids enhances patient independence at a relatively low cost.
Similar content being viewed by others
References and Recommended Reading
Kelly JJ Jr, Kyle RA, O’Brien PC, et al.: Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981, 31:1480–1483.
Keren DF, Warren JS, Lowe JB: Strategy to diagnose monoclonal gammopathies in serum: high resolution electrophoresis, immunofixation and kappa/lambda quantification. Clin Chem 1988, 34:2196–2201.
Kyle RA, Rajkumar SV: Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am 1999, 13:1181–1202.
Camacho J, Arnalich F, Anciones B, et al.: The spectrum of neurological manifestations in myeloma. J Med 1985, 16:597–611.
Kelly JJ Jr, Kyle RA, Miles JM, et al.: The spectrum of peripheral neuropathy in myeloma. Neurology 1981, 31:24–31.
Schey S: Osteosclerotic myeloma and "POEMS" syndrome. Blood Rev 1996, 10:75–80.
Bardwick PA, Zvaifler NJ, Gill GN, et al.: Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: The POEMS syndrome. Medicine 1980, 59:311–322.
Miralles GD, O’Fallon JR, Talley NJ: Plasma-cell dyscrasia with polyneuropathy. The spectrum of the POEMS syndrome. N Engl J Med 1992, 327:1919–1923.
Enevoldson TP, Harding AE: Improvement in the POEMS syndrome after administration of tamoxifen. J Neurol Neurosurg Psychiatry 1992, 55:71–72.
Ropper AH, Gorson KC: Neuropathies associated with paraproteinemia. N Engl J Med 1998, 338:1601–1607. This is an excellent, relatively brief review of the whole subject of paraproteinemic neuropathies, which provides a nice discussion of the spectrum of neuropathies seen with monoclonal proteins.
Gertz MA, Lacy MQ, Dispenzieri A: Amyloidosis. Hematol Oncol Clin North Am 1999, 13:1211–1233.
Dimopoulos MA, Galani E, Matsouka C: Waldenström’s macroglobulinemia. Hematol Oncol Clin North Am 1999, 13:1351–1367.
KisselJT, Mendell JR: Neuropathies associated with monoclonal gammopathies. Neuromusc Disord 1995, 6:3–18. This detailed overview of the subject is well-illustrated, and includes more detail on the diagnostic methods used to detect paraproteins.
Akriviadis EA, Xanthakis I, Navrozidou C, Papadopoulos A: Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha. J Clin Gastroenterol 1997, 25:612–618.
Dispenzieri A, Gorevic PD: Cryoglobulinemia. Hematol Oncol Clin North Am 1999, 13:1315–1349.
Apartis E, Leger JM, Musset L, et al.: Peripheral neuropathy associated with essential mixed cryoglobulinemia: a role for hepatitis C virus infection? J Neurol Neurosurg Psychiatry 1996, 60:661–666.
Durand JM, Cacoub P, Lunel-Fabiani F, et al.: Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 1998, 25:1115–1117.
Kelly JJ: Neuropathies of monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am 1999, 13:1203–1210.
Miescher GC, Latov N, Steck AJ: Dysglobulinemic neuropathies. In Neuroimmunology. Edited by Antel J, Birnbaum G, Hartung P. Cambridge: Blackwell Science; 1998:307–315.
Irie S, Kanazawa N, Ogino M, et al.: No cytomegalovirus DNA in sera from patients with anti-MAG/SGPG antibody-associated neuropathy. Ann Neurol 2000, 47:274–275.
Nobile-Orazio E, Manfredini E, Carpo M, et al.: Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994, 36:416–424.
KisselJT, Mendell JR: Neuropathies associated with monoclonal gammopathies. In Diagnosis and Management of Peripheral Nerve Disorders. Edited by Mendell JR, Kissel JT, Cornblath DR. New York; Oxford University Press: 2000:272–296. This very up-to-date chapter reviews all aspects of the subject, including detailed discussions of the neuropathies associated with the various hematologic disorders.
Katz JS, Saperstein DS, Gronseth G, et al.: Distal acquired demyelinating symmetric neuropathy. Neurology 2000, 54:615–620.
Gorson KC, Allam G, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997, 48:321–328. This detailed study is the largest published series that examines the difference between CIDP with and without an associated paraprotein.
Dyck PJ, Low PA, Windebank AJ, et al.: Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991, 325:1482–1486.
Notermans NC, Lokhorst HM, Franssen H, et al.: Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 1996, 47:1227–1233.
Mariette X, Brouet JC, Chevret S, et al.: A randomized double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 2000, 69:279–280.
Oksenhendler E, Chevret S, Leger JM, et al.: Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neurosurg Psychiatry 1995, 59:243–247.
Wilson HC, Lunn MPT, Schey S, Hughes RAC: Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 1999, 66:575–580.
Nobile-Orazio E, Meucci N, Baldini L, et al.: Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000, 123:710–717. Excellent overview of the long-term outlook for patients with anti-MAG-associated neuropathy. This report also examines the effects of immunotherapies on the natural history of the disease.
Gorson KC, Ropper AH, Weinberg DH, Weinstein R: Treatment experience in patients with antimyelinassociated glycoprotein neuropathy. Ann Neurol 2000, 48:441–442.
Blume G, Pestronk A, Goodnough LT: Anti-MAG antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 1995, 45:1577–1580.
Levine TD, Pestronk A: IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999, 52:1701–1704.
Rudnicki SA, Harik SI, Dhodapkar M, et al.: Nervous system dysfunction in Waldenström’s macroglobulinemia: Response to treatment. Neurology 1998, 51:1210–1213.
Sindrup SH, Jensen TS: Pharmacologic treatment of pain in polyneuropathy. Neurology 2000, 55:915–920.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wicklund, M.P., Kissel, J.T. Paraproteinemic neuropathy. Curr Treat Options Neurol 3, 147–156 (2001). https://doi.org/10.1007/s11940-001-0050-5
Issue Date:
DOI: https://doi.org/10.1007/s11940-001-0050-5